Member Login

    
              Click here if you forgot your password.

Current Events

Webinar: The new Annex 21

Tuesday, 21 April 2020
14.30 - 16.00 h

Webinar: The new EMA Reflection Paper on GMP and Marketing Authorisation Holders

Thursday, 23 April 2020
14.00 - 15.30 h


EQPA Members Area

IMP Working Group Members Area


Document and track your personal development - with the Continuous Professional Development (CPD) Documentation Template

To access the template for documenting and tracking your past and ongoing activities, please go here.

After filling out the form, you will be able to create and print out a PDF file.

ACAA with Israel: what the QP needs to know

12/06/2013

The ACAA agreement (Agreements on Conformity Assessment and Acceptance of Industrial Products) with Israel is a framework agreement that recognises Israeli industrial standards as equivalent to European standards and is similar to a Mutual Recognition Agreement (MRAs). The ACAA between the EU and Israel entered into force on 19 January 2013. The products covered by the ACAA include medicinal products, active pharmaceutical ingredients, pharmaceutical excipients or mixtures thereof, for human or veterinary use.

One of the most important regulations is the recognition of the conclusion of inspections. Similar to an MRA, GMP Certificates issued by either party are mutually recognised.

Very important for Qualified Persons (QP) are the regulations regarding batch certification, re-testing and release:
Each batch of medicinal product transferred from Israel to the EU must be accompanied by a batch certificate. In this case, no re-testing has to be performed by the importer, if the quality control site is located in Israel. But the QP still has to certify the batch. Certificates issued before the entry into force of the Agreement are covered as well. The internationally harmonised requirements for the content of the batch certificate are provided in Part 3 of the EU GMP Guide.

Note:
The following products are not covered by the ACAA:

  • medicinal products derived from human blood or human plasma,
  • advanced therapy medicinal products,
  • investigational medicinal products (IMPs),
  • homeopathic medicinal products,
  • medical gases and
  • veterinary immunologicals

Source:


 

Conference Recommendations